VIEW IN BROWSER

EDITOR'S NOTE: Big4Bio newsletters will not be published Nov 23rd-27th; they will resume distribution on Monday, Nov 30th.

November 17, 2026
Regional intelligence on Drugs, Diagnostics, Devices & Digital Health
* may need subscription to view
Big4Bio CEO Weekly - Q&A Life Sciences Leaders
BIG4BIO CEO WEEKLY Q&A:
 Oren Gilad, Ph.D., President & CEO, Aprea Therapeutics
In this Q&A, Gilad discusses what differentiates APR-1051 from earlier WEE1 inhibitors, the biomarker strategy behind Aprea's approach to precision oncology, milestones the company is working toward, and realities of leading a clinical-stage biotech through scientific and financial uncertainty. More

Press Releases

  • Alloy Therapeutics: Introduces TEMPER, a Proprietary siRNA Platform Designed to Advance Targeted Extrahepatic Delivery More
  • Asimov and Emergent Biosolutions: Cell Line Development Partnership to Advance Novel Antibodies Against Ebola More
  • Biogen and Eisai: New Five-Year Lecanemab Data From Clarity AD Study Long-Term Extension Presented at CTAD 2026 More
  • Biointron Biological: RushDATA Delivers Wet-Lab Validation for AI-Designed Antibodies From Molence Bio’s Mol-1 More
  • Cancer Research UK and Dewpoint Therapeutics: Partner to Advance Potential First-in-Class Myc Condensate Modulator Into Clinical Development More
  • CervoMed: Presents Interim Data at CTAD 2026 Showing Neflamapimod Reduces Neurodegeneration Biomarker in Nonfluent Variant Primary Progressive Aphasia More
  • Channel Medsystems: Brings Women New, Minimally Invasive Alternative Treatment With AcuityAI More
  • Cognito: Non-Invasive, At-Home Therapy, Spectris, Showed Consistent Slowing of Cognitive and Functional Decline in Early Symptomatic Alzheimer’s Disease in HOPE Pivotal Study More
  • Corsera Health: Initiates Phase 1 Trial of COR-1004 and COR-2003, a Novel Dual-Targeting RNAi Medicine to Prevent Cardiovascular Disease More
  • Ensem Therapeutics: Dosing of First Patients in Phase 1/2 Clinical Trial of ETX-929, a Potential Best-in-Class Oral Pan-KRAS Inhibitor More
  • Foundation Medicine: U.S. Food and Drug Administration Approves FoundationOne Liquid CDx as the First Companion Diagnostic in the U.S. for WILSERDLY (giredestrant) in Combination With Everolimus for ER-Positive, HER2-Negative, ESR1-Mutated Advanced Breast Cancer More
  • Genetix: Unveils Its Rapid Turnaround Into a Profitable, High-Growth Commercial Leader in Genetic Medicine for Rare Disease More
  • Instem: Unveils Unified, AI-Enabled Platform to Transform Preclinical R&D More
  • Nuclera and University of Cambridge: Researchers Demonstrate Rapid Structural Analysis of Challenging Drug Target More
  • ProMIS Neurosciences: Licenses Next-Generation TXP1 Brain-Selective Shuttling Technology From Ossianix to Expand PMN310 Franchise and Pipeline More
  • Quanterix: Expands Access to Blood-Based Alzheimer's Testing in New Jersey and Surrounding Area Through Exclusive Partnership with Sherman Abrams Laboratory More
  • Zenas BioPharma: Launches The Distance Between Platform to Bring Greater Visibility to the Hidden Burden of IgG4-Related Disease More

Financial News

CRCFO Advisory
Reassessing your business plan?
We provide financial leadership.
Smart. Nimble. Flexible.
Learn More  →
  • Biogen Inks $411M Neurodegeneration Pact With Protein Degrader Biotech TrimTech More More* More
  • Calytrix Bio: Enters an Agreement to Be Acquired by Lilly to Advance Outcomes for Patients Living With Essential Thrombocythemia and Myelofibrosis More More More More*
  • Cue Biopharma: Third Quarter 2026 Financial Results and Recent Business Highlights More
  • Enanta Pharmaceuticals: Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2026 More
  • Kernal Bio: Strategic Investment From IFLI and Leadership Appointments More
  • Keros Therapeutics: Additional $5 Million Share Repurchase Authorization More
  • Marrow Therapeutics: Launches With $173 Million to Develop Genetic Medicines for Bone Marrow Disorders More More More More*
  • Precision Optics: First Quarter Fiscal 2027 Financial Results More
  • Pulmatrix: Third Quarter 2026 Financial Results and Progress on Merger More
  • Rapid Micro Biosystems: Signs Definitive Agreement to be Acquired by Merck KGaA, Darmstadt, Germany More
  • Rapid Micro Biosystems: Third Quarter 2026 Financial Results More
  • Stipple Bio: Multi-Target Multi-Modality Oncology Research Collaboration With Lilly More More More*
  • Vyome: Sharp Reduction in Q3 2026 Loss Per Share; Advances Lead VT-1953 Program More

Media/Misc Coverage

Pace® Life Sciences

The CDMO That Takes You Further. Your partner for Product Development, Manufacturing, Analytical Testing, Regulatory Consulting & Operational Support.
Learn More  →
  • Big4Bio CEO Weekly Q&A: Oren Gilad, Ph.D., President & CEO, Aprea Therapeutics More
  • Biotech & Pharma Updates | November 16, 2026 More
  • Preparing for Commercial Launch In Oncology With Candel Therapeutics' Paul Peter Tak, M.D., Ph.D. Podcast
  • Subscribe to LifeSci Startup for Updates on US Startups More
evotec | Your next chapter in drug discovery starts with a conversation. Meet Evotec at JPM Week 2027. Book a meeting >

Career Moves

Slone Partners Places Farhad Ghavami as Chief Executive Officer at SeqCenter
Learn More  →
  • Harbour BioMed: Appoints Dr. Sanjay Keswani as Scientific Advisor in Neuroscience More
  • ICYMI: Bruker Institute Director, Biopharma Entrepreneur and Immunology Leader Dr. Eicke Latz Will Join Its Board of Directors More
  • ICYMI: Gubra CEO Gets the Quick Hook; Ex-HHS Official Brett Giroir Takes Over at Cancer Biotech More*
  • OPPORTUNITY: Director of Compliance, Remote More
  • OPPORTUNITY: Head of Market Development & Strategy, California More
  • OPPORTUNITY: Senior Vice President, Regulatory Affairs & Quality Assurance, Boston More
  • Slone Partners: Doing More With Less - Building the Right Nonprofit Leadership Team in a Resource-Constrained Environment More
  • Slone Partners: Leading Through AI - The New Playbook for Healthtech Executives More
On Your Mark 2027 | Every event of JPM Week. Jnauary 11-14, San Francisco. List your event - free. onyourmark.bio

Events

Note: Events may be in any Big4Bio region or virtual
Biotech Showcase, Jan 11-13
Learn More  →
  • Patient Pathways (Use code 26B4B10 for 10% off) Nov 17-20
  • Pricing & Contracting WEST (Use code 26B4B10 for 10% off) Dec 7-8
  • Trade and Channel Strategies (Use code 26B4B10 for 10% off) Dec 8-10
  • Advancing Drug Development Forum Dec 10
  • ABD Capital Connect JPM Healthcare Week Jan 11-12
  • Biotech Showcase Jan 11-13
  • 45th Annual J.P. Morgan Healthcare Conference Jan 11-14
  • PEGS AI Summit Jan 18-21
  • PepTalk 2027 Jan 18-21

SEE FULL EVENT SCHEDULE AT THE BIOCALENDAR

Companies

DISCOVER COMPANIES
Big4Bio: Boston Life Science Company Directory
Locate a specific company or explore new companies in life science.
Explore our Company Directory Provided courtesy of
BioPharmGuy Logo

Boston Sponsors



Follow us

Spotlights       Get Featured       Company Directory      News       Contact       Subscribe

You are receiving this email because you signed up for one of our newsletters at Big4Bio.com, signed up at one of our partner or sponsor events, or given as a gift subscription by your firm or organization. Unsubscribe

Big4Bio:Boston, all rights reserved 2026

© 2026 Big4Bio, a division of BigBio Communications. All rights reserved.